Table 4

Odds ratio for risk of being HCV RNA negative among European American and African American injection drug users, by MBL2 secretor haplotype profile.

Haplotype frequency estimates


Secretor Haplotype

Total

HCV RNA Negative

HCV RNA Positive

P

OR (95% CI)


European Americans

-618

-289

-65

Ex1 -34

Ex1 -27

Ex1 -18

HYPA

G

G

C

C

G

G

32.3%

29.2%

33.2%

0.24

referent

LYQA

C

G

T

C

G

G

21.2%

18.5%

22.1%

0.23

0.93 (0.58–1.51)

LXPA

C

C

C

C

G

G

19.5%

25.2%

17.7%

0.01

1.73 (1.10–2.74)

LYPB

C

G

C

C

A

G

12.9%

11.5%

13.3%

0.49

0.93 (0.53–1.64)

HYPD

G

G

C

T

G

G

6.5%

6.9%

6.4%

0.66

1.19 (0.59–2.39)

LYPA

C

G

C

C

G

G

5.1%

5.0%

5.1%

0.94

0.92(0.40–2.13)

LYQC

C

G

T

C

G

A

2.5%

3.9%

2.0%

0.08

3.27 (1.18–9.05)

Global score statistic

0.14


African Americans

LYQA

C

G

T

C

G

G

27.3%

24.8%

28.0%

0.38

referent

LYQC

C

G

T

C

G

A

25.7%

27.0%

25.3%

0.69

1.24 (0.76–2.01)

LYPA

C

G

C

C

G

G

16.5%

18.4%

15.9%

0.49

1.24(0.70–2.21)

LXPA

C

C

C

C

G

G

15.4%

15.6%

15.4%

0.89

1.23 (0.69–2.18)

HYPA

G

G

C

C

G

G

10.7%

9.8%

10.9%

0.74

1.10 (0.57–2.12)

LYPB

C

G

C

C

A

G

3.4%

3.4%

3.4%

0.91

1.15 (0.44–3.01)

HYPD

G

G

C

T

G

G

1.0%

1.1%

1.0%

0.92

1.21 (0.23–6.29)

Global score statistic

0.98


Relative haplotype frequencies adjusted for sex, duration of injection drug use and HIV-1 serostatus.

Haplotypes appear in order of descending haplotype frequencies among the comparison group stratified by race.

P-value for LYPC among European Americans is not statistically signficant due to permutations based on small haplotype frequencies.

The global score test evaluates differences between cases and controls in the overall haplotype distribution.

Brown et al. BMC Infectious Diseases 2008 8:57   doi:10.1186/1471-2334-8-57

Open Data